Phase II evaluation of doxorubicin/vinblastine combined with Inhibitors trifluoperazine/verapamil of P-glycoprotein in patients with advanced renal carcinoma

Urologic Oncology

Volumn 3, Issue 3, 1997, Pages 94-98

  Schroder, Louis E ^a   Blumenstein, Brent A ^b   Flanigan, Robert L ^c   Borst, James R ^d   Crawford, E David ^e  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b SW Oncol Group Statistical Center   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d GRAND RAPIDS CLINICAL ONCOLOGY PROGRAM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemotherapy; Multidrug resistance; P glycoprotein; Renal carcinoma

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; TRIFLUOPERAZINE; VERAPAMIL; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRANULOCYTOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEUKOPENIA; MALE; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS;

EID: 0031411080     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(97)00053-7     Document Type: Review

References (19)

1. Kuboch J. Survey of chemotherapy of metastatic renal cancer. Sem Surg Oncol 1988;4:87-90.
2. Yagoda A, Abu-Rached B, Petrylak D. Chemotherapy for advanced renal cell carcinoma, 1983-1993. Sem Onc 1995;22(1): 42-60.
3. Pyrohnen S, Salminen E, Lehtonen T, et al. Recombinant Interferon alfa-2A with vinblastine vs vinblastine alone in advanced renal cell carcinoma, a Phase III study. ASCO Proc 1996;15:244.
4. Lum BL, Gosland MP, Kaubisch S, Sikic B. Molecular targets in oncology: Implications of the multidrug resistance gene. Pharmacotherapy 1993;13(2):88-109.
5. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic and cytogenetic studies. Cancer Res 1970;30:1174-84.
6. Bech-Hanson NT, Till JE, Ling V. Pleiotropic phenotype of colchicine-resistant CHO cells: Cross resistance and collateral sensitivity. J Cell Physiol 1976;88:23-32.
7. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62.
8. Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv in Clin Chem 1994;31:1-61.
9. Chapman AE, Goldstein LJ. Multiple drug resistance: Biological basis and clinical significance in renal-cell carcinoma. Sem Oncol 1995;22:17-28.
10. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-99.
11. Willingham MC, Cornwell MM, Cardarelli CO, et al. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and sensitive KB cells: Effects of verapamil and other drugs. Cancer Res 1986;46:5941-6.
12. Murphy BR, Rynard SM, Pennington KL, et al. A phase II trial of vinblastine plus dipyridamole in advanced renal cell carcinoma. Am J Clin Oncol 1994;17:10-3.
13. Rodenberg CJ, Nooter K, Herwijer H, et al. Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991;2:305-6.
14. Mikisch GH, Noordzij MA, v.d. Gaast A, et al. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol 1995;121(suppl 3):R11-R16.
15. Motzer RJ, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995;13:1958-65.
16. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Hem/Oncol Clin North Am 1995;9(2):363-82.
17. Miller RL, Bukowski RM, Budd GT, et al. Clinical modulation doxorubicin resistance by the calmodulin inhibitor trifluoperazine: A phase II trial. J Clin Oncol 1988;5:880-8.
18. Mickisch G, Bier H, Bergler W, et al. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol Int 1990;45:170-6.
19. Volm M, Mattern J, Efferth T, Pommerenke EW. Expression of several resistance mechanisms in untreated human kidney and lung cancers. Anticancer Res 1992;12:1063-8.